We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Krystal Biotech, Inc.는 상업화 단계의 생명공학 기업으로, 미국 내 미충족 의료 수요가 높은 질병 치료를 위한 유전자 치료제를 발굴, 개발, 제조 및 상업화하고 있습니다. 회사는 이영양성 수포성 표피박리증 (DEB) 치료제인 VYJUVEK (beremagene geperpavec-svdt, 또는 B-VEC)을 상업화하고 있습니다. 또한, 이영양성 수포성 표피박리증(DEB)의 안과 합병증 치료를 위한 KB803, 신경영양성 각막염 치료를 위한 KB801, 낭포성 섬유증 치료를 위해 1상 임상 시험